Bristol-Myers Squibb

Five Prime Therapeutics, Bristol-Myers Squibb collaborate

Monday, March 17, 2014 01:37 PM

Five Prime Therapeutics, a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, and Bristol-Myers Squibb (BMS) have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform.

More... »


Report: pharmacovigilance market, service providers to reach $5B globally in 2019

Friday, February 28, 2014 12:02 PM

According to a new market report published by Transparency Market Research, the global pharmacovigilance market was valued at $2,147.3 million in 2012 and is estimated to reach a market worth $5,008.2 million in 2019, at a CAGR of 12.9% from 2013 to 2019.

More... »


Inovio Pharmaceuticals expands senior management team

Friday, February 21, 2014 02:38 PM

Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as vice president of R&D and Dr. Jan Marie-Albert Van Tornout as vice president of Clinical Development.

More... »

Spark Therapeutics appoints Elliott Sigal to board of directors

Friday, February 14, 2014 01:27 PM

Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, has appointed Elliott Sigal, M.D., Ph.D., former director, executive vice president and chief scientific officer of Bristol-Myers Squibb, to its board of directors. Elliott led Bristol-Myers Squibb during its ascent as a biopharmaceutical leader and built one of the industry's most productive R&D organizations through his forward-thinking approach to innovation.

More... »

Innate Pharma acquires ANTI-NKG2A from Novo Nordisk

Monday, February 10, 2014 10:19 AM

Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody, a first-in-class immune checkpoint inhibitor ready for phase II development in oncology from global healthcare company Novo Nordisk.

More... »

Report: Absence of 2014 blockbuster drug launches puts R&D productivity at risk

Monday, February 10, 2014 09:54 AM

The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to a new report from EP Vantage, a source of life science market intelligence and analysis.

More... »

NIH, industry and nonprofits join forces to speed validation of disease targets

Wednesday, February 5, 2014 01:02 PM

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations have launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

More... »

Bristol-Myers Squibb completes sale of global diabetes business to AstraZeneca

Monday, February 3, 2014 08:51 AM

Bristol-Myers Squibb has completed the previously announced sale of its global diabetes business to AstraZeneca.

More... »

Bristol-Myers Squibb names three research project winners for in viral diseases

Friday, January 31, 2014 11:31 AM

Three European virology researchers were awarded research grants this week based on their proposed research projects to investigate novel ways to cure viral diseases. The award-winners were chosen by an independent faculty as part of the Partnering for Cure Program, a first-of-its kind, Europe-wide initiative. The program, sponsored by Bristol-Myers Squibb, is designed to accelerate innovative scientific research that could lead to cure in viral diseases, namely HIV, hepatitis B (HBV) and hepatitis C (HCV).

More... »

TransCelerate releases update on risk-based monitoring initiative

Thursday, January 30, 2014 10:43 AM

In its continued effort to modernize and streamline the way clinical trials are conducted and monitored, TransCelerate BioPharma has providing the first update to its position paper outlining a methodology for risk-based site monitoring (RBM) released in June 2013.

More... »

CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs